|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 November 2000, Vol. 96, No. 9, pp. 3118-3125
IMMUNOBIOLOGY
Correlation of mutations of the SH2D1A gene and
Epstein-Barr virus infection with clinical phenotype and outcome in
X-linked lymphoproliferative disease
Janos Sumegi,
Dali Huang,
Arpad Lanyi,
Jack D. Davis,
Thomas A. Seemayer,
Akihiko Maeda,
George Klein,
Marco Seri,
Hiroshi Wakiguchi,
David T. Purtilo, and
Thomas G. Gross
From the Department of Pathology and Microbiology,
Center for Human Molecular Genetics, Eppley Institute for Research in
Cancer and Allied Diseases; the Departments of Pathology and
Microbiology and Pediatrics, University of Nebraska Medical Center,
Omaha, NE; the Center for Microbiology and Tumorbiology, Karolinska
Institute, Stockholm, Sweden; the Laboratorio di Genetica Molecolare,
Instituto Giannina Gaslini, Genoa, Italy; the Department of Pediatrics,
Kochi Medical School, Nankoku, Japan; and the Division of Hematology
and Oncology, Children's Hospital Medical Center, Cincinnati, OH.
The purposes of this study were to determine the frequency of
mutations in SH2D1A in X-linked lymphoproliferative disease (XLP) and
the role of SH2D1A mutations and Epstein-Barr virus (EBV) infection in
determining the phenotype and outcome of patients with XLP. Analysis of
35 families from the XLP Registry revealed 28 different mutations in 34 families large genomic deletions (n = 3), small intragenic deletions
(n = 10), splice-site (n = 3), nonsense (n = 3), and missense
(n = 9) mutations. No mutations were found in 25 males, so-called
sporadic XLP (males with an XLP phenotype after EBV infection but
no family history of XLP) or in 9 patients with chronic active EBV
syndrome. Of 304 symptomatic males in the XLP Registry, 38 had no
evidence of EBV infection at first clinical manifestation. When
fulminant infectious mononucleosis (FIM) was excluded, there was no
statistical difference in the frequency of EBV infectivity in the other
XLP phenotypes. Furthermore, there was no difference at age of first
clinical manifestation between EBV+ and EBV
males or in survival when patients with FIM were excluded. In conclusion, it was found that mutations in the SH2D1A gene are responsible for XLP but that there is no correlation between genotype and phenotype or outcome. It was also found that though EBV infection often results in FIM, it is unnecessary for the expression of other
manifestations of XLP, and it correlates poorly with outcome. These
results suggest that unidentified factors, either environmental or
genetic (eg, modifier genes), contribute to the pathogenesis of XLP.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Chaganti, C. S. Ma, A. I. Bell, D. Croom-Carter, A. D. Hislop, S. G. Tangye, and A. B. Rickinson
Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM+IgD+CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients
Blood,
August 1, 2008;
112(3):
672 - 679.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-C. Hsieh, Y. Chang, M.-C. Hsu, B.-S. Lan, G.-C. Hsiao, H.-C. Chuang, and I.-J. Su
Emergence of Anti-Red Blood Cell Antibodies Triggers Red Cell Phagocytosis by Activated Macrophages in a Rabbit Model of Epstein-Barr Virus-Associated Hemophagocytic Syndrome
Am. J. Pathol.,
May 1, 2007;
170(5):
1629 - 1639.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mischler, G. M. Fleming, T. P. Shanley, L. Madden, J. Levine, V. Castle, A. H. Filipovich, and T. T. Cornell
Epstein-Barr Virus-Induced Hemophagocytic Lymphohistiocytosis and X-Linked Lymphoproliferative Disease: A Mimicker of Sepsis in the Pediatric Intensive Care Unit
Pediatrics,
May 1, 2007;
119(5):
e1212 - e1218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Crotty, M. M. McCausland, R. D. Aubert, E. J. Wherry, and R. Ahmed
Hypogammaglobulinemia and exacerbated CD8 T-cell-mediated immunopathology in SAP-deficient mice with chronic LCMV infection mimics human XLP disease
Blood,
November 1, 2006;
108(9):
3085 - 3093.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gu, S. G. Tangye, X. Sun, Y. Luo, Z. Lin, and J. Wu
The X-linked lymphoproliferative disease gene product SAP associates with PAK-interacting exchange factor and participates in T cell activation
PNAS,
September 26, 2006;
103(39):
14447 - 14452.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Hare, C. S. Ma, F. Alvaro, K. E. Nichols, and S. G. Tangye
Missense mutations in SH2D1A identified in patients with X-linked lymphoproliferative disease differentially affect the expression and function of SAP
Int. Immunol.,
July 1, 2006;
18(7):
1055 - 1065.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Williams and D. H. Crawford
Epstein-Barr virus: the impact of scientific advances on clinical practice
Blood,
February 1, 2006;
107(3):
862 - 869.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Al-Alem, C. Li, N. Forey, F. Relouzat, M.-C. Fondaneche, S. V. Tavtigian, Z.-Q. Wang, S. Latour, and L. Yin
Impaired Ig class switch in mice deficient for the X-linked lymphoproliferative disease gene Sap
Blood,
September 15, 2005;
106(6):
2069 - 2075.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Dupre, G. Andolfi, S. G. Tangye, R. Clementi, F. Locatelli, M. Arico, A. Aiuti, and M.-G. Roncarolo
SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells
Blood,
June 1, 2005;
105(11):
4383 - 4389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Tabata, J. Villanueva, S. M. Lee, K. Zhang, H. Kanegane, T. Miyawaki, J. Sumegi, and A. H. Filipovich
Rapid detection of intracellular SH2D1A protein in cytotoxic lymphocytes from patients with X-linked lymphoproliferative disease and their family members
Blood,
April 15, 2005;
105(8):
3066 - 3071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Gross
SLAM "dunked"?
Blood,
May 15, 2004;
103(10):
3613 - 3614.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Malbran, L. Belmonte, B. Ruibal-Ares, P. Bare, I. Massud, C. Parodi, M. Felippo, R. Hodinka, K. Haines, K. E. Nichols, et al.
Loss of circulating CD27+ memory B cells and CCR4+ T cells occurring in association with elevated EBV loads in XLP patients surviving primary EBV infection
Blood,
March 1, 2004;
103(5):
1625 - 1631.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Tracey, R. Villuendas, P. Ortiz, A. Dopazo, I. Spiteri, L. Lombardia, J. L. Rodriguez-Peralto, J. Fernandez-Herrera, A. Hernandez, J. Fraga, et al.
Identification of Genes Involved in Resistance to Interferon-{alpha} in Cutaneous T-Cell Lymphoma
Am. J. Pathol.,
November 1, 2002;
161(5):
1825 - 1837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Shinozaki, H. Kanegane, H. Matsukura, R. Sumazaki, M. Tsuchida, M. Makita, Y. Kimoto, R. Kanai, K. Tsumura, T. Kondoh, et al.
Activation-dependent T cell expression of the X-linked lymphoproliferative disease gene product SLAM-associated protein and its assessment for patient detection
Int. Immunol.,
October 1, 2002;
14(10):
1215 - 1223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Schuster, K. Steppberger, M. Borte, R. Tan, J. Dutz, L. Benoit, D. de Sa, and A. Junker
Manifestations of X-linked lymphoproliferative disease without prior Epstein-Barr virus exposure
Blood,
September 15, 2001;
98(6):
1986 - 1987.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Nakamura, J. Zarycki, J. L. Sullivan, and J. U. Jung
Abnormal T Cell Receptor Signal Transduction of CD4 Th Cells in X-Linked Lymphoproliferative Syndrome
J. Immunol.,
September 1, 2001;
167(5):
2657 - 2665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Morra, O. Silander, S. Calpe, M. Choi, H. Oettgen, L. Myers, A. Etzioni, R. Buckley, and C. Terhorst
Alterations of the X-linked lymphoproliferative disease gene SH2D1A in common variable immunodeficiency syndrome
Blood,
September 1, 2001;
98(5):
1321 - 1325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Sumazaki, H. Kanegane, M. Osaki, T. Fukushima, M. Tsuchida, H. Matsukura, K. Shinozaki, H. Kimura, A. Matsui, and T. Miyawaki
SH2D1A mutations in Japanese males with severe Epstein-Barr virus-associated illnesses
Blood,
August 15, 2001;
98(4):
1268 - 1270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Czar, E. N. Kersh, L. A. Mijares, G. Lanier, J. Lewis, G. Yap, A. Chen, A. Sher, C. S. Duckett, R. Ahmed, et al.
Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP
PNAS,
June 7, 2001;
(2001)
131193098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Morra, M. Simarro-Grande, M. Martin, A. S.-I. Chen, A. Lanyi, O. Silander, S. Calpe, J. Davis, T. Pawson, M. J. Eck, et al.
Characterization of SH2D1A Missense Mutations Identified in X-linked Lymphoproliferative Disease Patients
J. Biol. Chem.,
September 21, 2001;
276(39):
36809 - 36816.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Czar, E. N. Kersh, L. A. Mijares, G. Lanier, J. Lewis, G. Yap, A. Chen, A. Sher, C. S. Duckett, R. Ahmed, et al.
Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP
PNAS,
June 19, 2001;
98(13):
7449 - 7454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
